Bio-Path receives new patents for P-ethoxy nucleic acids

Bio-Path (BPTH) announced the receipt of newly issued patents in the United States and New Zealand, and updated investors on the extent of its global intellectual property portfolio. Bio-Path received notice of allowance from the United States Patent and Trademark Office for U.S. Patent No. 17/339,366 titled, “P-ethoxy nucleic acids for STAT3 inhibition.” The New Zealand Intellectual Property Office has granted Patent No. 741793 titled, “P-ethoxy nucleic acids for liposomal formulation.” These new patents build on earlier patents granted that protect the platform technology for DNAbilize, the company’s RNAi nanoparticle drugs.